<SEC-DOCUMENT>0001171843-20-007004.txt : 20201013
<SEC-HEADER>0001171843-20-007004.hdr.sgml : 20201013
<ACCEPTANCE-DATETIME>20201013063008
ACCESSION NUMBER:		0001171843-20-007004
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20201013
FILED AS OF DATE:		20201013
DATE AS OF CHANGE:		20201013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		201234481

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_101220.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong>Date of report:&#160;</strong><strong>For the month of October 2020</strong></p><p style="text-align: center;"><strong>Commission File Number: 001-39084</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Innate Pharma S.A.</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>Innate Pharma S.A.<br />117 Avenue de Luminy&#8212;BP 30191<br />13009 Marseille, France <br />+ 33 (0) 4 30 30 30 &#160;</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p>Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </p><hr style="page-break-after: always;" noshade="noshade" /><p>
 <p align="center"><font style="font-size:10pt;"><strong>EXHIBIT INDEX</strong></font></p>   <p align="center" style="text-align: center;"><font style="font-size:10pt;">&#160;</font></p>  <table style="border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><strong><u>Exhibit</u></strong></font></td><td class="hugin"><font style="font-size:10pt;">&#160; &#160; &#160;&#160;</font></td><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><strong><u>Description</u></strong></font></td></tr><tr><td class="hugin">&#160;</td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td></tr><tr><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">99.1</a></font></font></font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">Press Release dated October 13, 2020 </a></font></font></font></td></tr></table></p><p /><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td>&#160;</td><td>&#160;</td><td style="text-transform: uppercase;" colspan="2"><strong>Innate Pharma S.A.</strong></td></tr><tr valign="top"><td style="width: 47%;">&#160;</td><td style="width: 6%;">&#160;</td><td style="text-align: center; width: 10%;">&#160;</td><td style="text-align: center; width: 84%;">&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr><tr valign="top"><td>Date: October 13, 2020</td><td>&#160;</td><td>By:</td><td style="border-bottom: black 1pt solid;">/s/ Laure-H&#233;l&#232;ne Mercier&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Name:&#160;&#160;&#160;&#160;&#160;</td><td>Laure-H&#233;l&#232;ne Mercier</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Title:</td><td>Chief Financial Officer</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Number of Shares and Voting Rights of Innate Pharma as of October 1, 2020</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <p align="justify">Pursuant to the article L. 233-8 II of the French &#8220;Code de Commerce&#8221; and the article 223-16 of the French stock-market authorities (<em>Autorit&#233; des March&#233;s Financiers</em>, or &#8220;AMF&#8221;) General Regulation, Innate Pharma SA (Euronext Paris: IPH &#8211; ISIN: FR0010331421; Nasdaq: IPHA) (&#8220;<strong>Innate</strong>&#8221; or the &#8220;<strong>Company</strong>&#8221;) releases its total number of shares outstanding as well as its voting rights as at October 1, 2020:<br ></p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:55%; width:55%; min-width:55%;;text-align: left ;  vertical-align: middle; vertical-align: top ; ">Total number of shares outstanding:</td><td style="max-width:45%; width:45%; min-width:45%;;text-align: left ;  vertical-align: middle; vertical-align: top ; ">78,981,290 ordinary shares</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">6,921 Preferred Shares 2016 <br ></td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">7,581 Preferred Shares 2017</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">Total number of theoretical voting rights (1): <br ></td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">79,799,621 <br ></td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">Total number of exercisable voting rights (2):</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">79,781,046</td></tr></table> <p align="justify"><em>(1) The total number of theoretical voting rights (or &#8220;gross&#8221; voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes (i) voting rights attached to AGAP 2016 (2016 Preferred Shares), i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2 and (ii) voting rights attached to AGAP 2017, i.e. 1 voting right per AGAP 2017.</em></p>  <p align="justify"><em>(2) The total number of exercisable voting rights (or &#8220;net&#8221; voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.</em></p>  <p align="justify"><strong>About Innate Pharma:</strong></p>  <p align="justify">Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.</p>  <p align="justify">Innate Pharma&#8217;s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma&#8217;s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.</p>  <p align="justify">Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.</p>  <p align="justify">Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.</p>  <p align="justify">Learn more about Innate Pharma at <u>www.innate-pharma.com </u></p>  <p align="justify"><strong>Information about Innate Pharma shares:</strong></p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:45%; width:45%; min-width:45%;;text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>ISIN code</strong><br ></td><td style="max-width:55%; width:55%; min-width:55%;;text-align: left ;  vertical-align: middle; vertical-align: top ; ">FR0010331421<br ></td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>Ticker code</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">Euronext: IPH Nasdaq: IPHA</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>LEI</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">9695002Y8420ZB8HJE29</td></tr></table> <p align="justify"><strong>Disclaimer on forward-looking information and risk factors: </strong></p>  <p align="justify">This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts, the Company&#8217;s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company&#8217;s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.</p>  <p align="justify">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.</p>  <p align="justify"><strong>For additional information, please contact:</strong></p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:50%; width:50%; min-width:50%;;text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong><u>Investors</u></strong> <br ><br > <strong>Innate Pharma</strong><br > Tel.: +33 (0)4 30 30 30 30 <br > <u>investors@innate-pharma.com</u> <br ><br > <br ><br > <br ><br ></td><td style="max-width:50%; width:50%; min-width:50%;;text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong><u>Media</u></strong> <br ><br > <strong>Innate Pharma </strong><br > Tracy Rossin (Global/US) <br > Tel.: +1 240 801 0076 <br > <u>Tracy.Rossin@innate-pharma.com</u> <br ><br > <strong>ATCG Press </strong><br > Marie Puvieux (France) <br > Tel.: +33 (0)9 81 87 46 72 <br > <u>innate-pharma@atcg-partners.com</u></td></tr></table></p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
